FEDERALhearing transcript

Congressional Hearing: Repurposing Existing Drugs for COVID-19 Treatment

Original title: REPURPOSING THERAPEUTIC DRUGS FOR COVID-19: RESEARCH CHALLENGES AND OPPORTUNITIES

January 1, 2021

COVID-19 drug repurposing public health medical research scientific oversight

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing examines the scientific standards used by federal agencies to determine if existing, FDA-approved drugs can be safely and effectively used to treat COVID-19, impacting how quickly new treatment options reach patients.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Medical Researchers

Researchers are involved in the clinical trials and data analysis required to validate repurposed drugs.

Public Health Agencies

These agencies are responsible for the evaluation and regulatory oversight of drug repurposing protocols.

What changed

Last recorded activity January 1, 2021.

What's next

Next step not available in the current record.

Summary

This document is a transcript of a June 19, 2020, House Subcommittee hearing regarding the scientific challenges and opportunities of using already-approved medications to treat COVID-19. The hearing focused on the federal government's evaluation process for these drugs during the pandemic.

Key Facts

The hearing was held virtually on June 19, 2020, via Webex, pursuant to House Resolution 965.
The primary subject is the scientific evaluation of repurposing existing therapeutic drugs for COVID-19 treatment.
The hearing was the first virtual meeting of the Committee on Investigations and Oversight.
The subcommittee heard testimony from experts in public health, respiratory medicine, computing/life sciences, and clinical research.
The hearing record includes written statements from the Chairwoman, Ranking Member, and four expert witnesses.

Frequently Asked Questions

What does 'repurposing drugs' mean in this context?

It refers to taking medications that have already been developed and approved for other conditions and testing whether they are effective at treating COVID-19.

Why was this hearing held virtually?

The hearing was held virtually due to the COVID-19 pandemic, following the procedures established in House .

Why It Matters

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

temporal pattern100% confidence

Early Pandemic Virtual Transition

The document captures the specific moment in June 2020 when Congressional committees were transitioning to virtual operations via Webex.

Subcommittee on Investigations and Oversight

Connected Entities

personPeter Lurie“President of the Center for Science in the Public Interest”Map →

personBill Foster“Chairman of the Subcommittee on Investigations and Oversight”Map →

organizationSubcommittee on Investigations and Oversight“Committee on Science, Space, and Technology”Map →

personRick L. Stevens“Associate Laboratory Director at Argonne National Laboratory”Map →

personJames Finigan“Director of the Respiratory Centers of Excellence, National Jewish Health”Map →

personBenjamin Rome“Associate Physician at Brigham and Women's Hospital”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance65
How much this matters to a regular citizen
Controversy20
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz15
Current news / social attention level

Publisher tools